New AI weapon in fight against prostate cancer

Lucida’s Pi (Prostate Intelligence) solution will now be delivered to healthcare professionals via the Blackford platform – accelerating diagnosis and treatment.

Pi has been designed to help healthcare professionals work more quickly by automating laborious steps and to increase accuracy for detection of clinically significant prostate cancer.

Prostate cancer is the most common male cancer with case numbers forecast to double by 2040; however, up to 50 per cent of cases are currently being diagnosed late – at stages III-IV.

Dr Antony Rix, Co-Founder and CEO at Lucida Medical, says: “Recent research has shown that Pi has expert-level performance in real-world applications across multiple healthcare settings, scanner types and vendors.

“We are delighted to work with Blackford to offer Pi to hospitals across the UK and Europe to help clinical teams save time and offer their patients the best possible diagnosis and treatment for prostate cancer.”

Blackford provides healthcare professionals with access to a portfolio of more than 120 AI solutions designed to drive clinical accuracy and efficiency and improve patient outcomes.

By integrating Lucida Medical’s advanced technology into the Blackford Platform, Blackford can offer healthcare providers more powerful tools to support analysis of prostate MRIs.

“Our partnership with Lucida Medical enhances our ability to provide healthcare professionals with AI to help deliver more precise and efficient prostate cancer diagnosis and care.” says Ben Panter, Founder and CEO of Blackford.

“We are delighted to integrate the Pi solution into our extensive AI portfolio aimed at empowering clinicians with the tools they need to make informed decisions, ultimately improving patient outcomes.”